BioCryst Pharmaceuticals down after quarterly revenue miss
ReutersNov 3, 2025 6:24 PM
Shares of drugmaker BioCryst Pharmaceuticals BCRX.O down ~ 4% at $7.03
Posts Q3 revenue of $159.4 million, missing analysts' estimate of $163 million- data compiled by LSEG
BCRX narrows 2025 revenue forecast for its skin disease drug orladeyo to between $590 million and $600 million from $580 million and $600 million
Up to last close stock down nearly 3%, YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
US Stock November Prediction: Investors Weigh Seasonal Rally Against Concerns Over AI Valuations
TradingKey - After the S&P 500 Index posted its longest monthly winning streak since August 2021 with six consecutive gains, a hawkish Federal Reserve and concerns over artificial intelligence (AI) valuations have clouded the start of November for U.S. equities. Amidst a broad tech sector pullbackTradingKey
14 hours ago
When Will Elon Musk Send Dogecoin to the Moon? Will DOGE Price Soar?
Dogecoin, the original and largest meme coin by market capitalization, is poised for a significant price catalyst by year-end. A long-time favorite of Elon Musk, the cryptocurrency has garnered his support on multiple occasions. The crypto market is now eagerly awaiting Musk's planned mission to senTradingKey
17 hours ago
Strategy (MSTR): Why This Bitcoin Proxy Is Decoupling From BTC — And Is It Still a Buy?
TradingKey - Strategy stock is in a sustained decline and remains entrenched in a downward channel, as Bitcoin continues to fall and briefly dipped below $100,000 on November 4, leading to a sharp decline in Bitcoin-related stocks. We believe Strategy’s slump has not yet abated.TradingKey
Thu, Nov 6
Tesla’s 2025 Shareholder Meeting Showdown: Musk’s Leadership and Tesla’s Crossroads
TradingKey - Tesla (TSLA), the electric vehicle leader, will hold its 2025 Annual Shareholder Meeting on November 6. Dubbed by CEO Elon Musk as a moment that will “decide Tesla’s future and shape the world’s,” the event centers on one pivotal question: Will shareholders approve Musk’s proposed $1 TTradingKey
Wed, Nov 5
Palantir Q3 2025 Earnings: Blowout Performance Can’t Hide an AI Bubble， Four Growing Risks Behind a Nearly 1,000x Valuation
TradingKey – After the close of trading on November 4, “AI application King” Palantir Technologies (PLTR) reported its third-quarter earnings for fiscal year 2025. Despite a blowout quarter, surging top-line growth, and a flood of commercial orders, the stock plunged in after-hours trading.TradingKey
Tue, Nov 4
